These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23727044)

  • 1. Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
    Ryu BJ; Kim N; Kim JT; Koo TS; Yoo SE; Jeong SH; Kim SH; Kang NS
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3887-90. PubMed ID: 23727044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
    Bradbury RH; Acton DG; Broadbent NL; Brooks AN; Carr GR; Hatter G; Hayter BR; Hill KJ; Howe NJ; Jones RD; Jude D; Lamont SG; Loddick SA; McFarland HL; Parveen Z; Rabow AA; Sharma-Singh G; Stratton NC; Thomason AG; Trueman D; Walker GE; Wells SL; Wilson J; Wood JM
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1945-8. PubMed ID: 23466225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivalent peptidomimetic conjugates: a versatile platform for modulating androgen receptor activity.
    Levine PM; Imberg K; Garabedian MJ; Kirshenbaum K
    J Am Chem Soc; 2012 Apr; 134(16):6912-5. PubMed ID: 22509763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
    Kandil S; Westwell AD; McGuigan C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.
    Bradbury RH; Hales NJ; Rabow AA; Walker GE; Acton DG; Andrews DM; Ballard P; Brooks NA; Colclough N; Girdwood A; Hancox UJ; Jones O; Jude D; Loddick SA; Mortlock AA
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5442-5. PubMed ID: 21782422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.
    Guo C; Pairish M; Linton A; Kephart S; Ornelas M; Nagata A; Burke B; Dong L; Engebretsen J; Fanjul AN
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2572-8. PubMed ID: 22377517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
    Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
    Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell.
    Cruz EC; Carecho AR; Saidel ME; Montanari CA; Leitão A
    Bioorg Med Chem Lett; 2017 Feb; 27(3):546-550. PubMed ID: 28011219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
    Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
    J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).
    Ban F; Leblanc E; Li H; Munuganti RS; Frewin K; Rennie PS; Cherkasov A
    J Med Chem; 2014 Aug; 57(15):6867-72. PubMed ID: 25025737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,2,4-Oxadiazoles: a new class of anti-prostate cancer agents.
    Khatik GL; Kaur J; Kumar V; Tikoo K; Nair VA
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1912-6. PubMed ID: 22326399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
    Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
    Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.
    Guo C; Kephart S; Ornelas M; Gonzalez J; Linton A; Pairish M; Nagata A; Greasley S; Elleraas J; Hosea N; Engebretsen J; Fanjul AN
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1230-6. PubMed ID: 22197140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and anticancer activities of new 3-allylthio-6-(mono or disubstituted)aminopyridazines.
    Won YH; Park MS
    Arch Pharm Res; 2010 Feb; 33(2):189-96. PubMed ID: 20195817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.
    Caboni L; Kinsella GK; Blanco F; Fayne D; Jagoe WN; Carr M; Williams DC; Meegan MJ; Lloyd DG
    J Med Chem; 2012 Feb; 55(4):1635-44. PubMed ID: 22280402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.